Scheduled Carcinogenic Substances Listing

PROHIBITED CARCINOGENIC SUBSTANCES
SCHEDULE 1

Substance Name [Chemical Abstract Number

2-Acetylaminofluorene [53-96-3]
Aflatoxins
4-Aminodiphenyl [92-67-1]
Amosite [12172-73-5] (brown asbestos)
— except for removal and disposal purposes
and situations where amosite occurs naturally
and is not used for any new application.
Benzidine [92-87-5] and its salts (including
benzidine dihydrochloride [531-85-1])
bis(Chloromethyl) ether [542-88-1]
Chloromethyl methyl ether [107-30-2] (technical
grade which contains bis(chloromethyl) ether)
Crocidolite [12001-28-4] (blue asbestos)
— except for removal and disposal purposes
and situations where crocidolite occurs naturally
and is not used for any new application.
4-Dimethylaminoazobenzene [60-11-7]
2-Naphthylamine [91-59-8] and its salts
4-Nitrodiphenyl [92-93-3]

NOTIFIABLE CARCINOGENIC SUBSTANCES
SCHEDULE 2

Substance Name [Chemical Abstract Number]

Acrylonitrile [107-13-1]
Benzene [71-43-2] — when used as a feedstock
containing more than 50% of benzene by volume
Chrysotile [12001-29-5] (white asbestos)
— when used for the manufacture of asbestos products.
Cyclophosphamide [50-18-0] (cytotoxic drug) . when
used in preparation for therapeutic use in hospitals
and oncological treatment facilities, and in manufacturing
operations
3,3'-Dichlorobenzidine [91-94-1] and its salts (including
3,3'-Dichlorobenzidine dihydrochloride [612-83-9])
Diethyl sulfate [64-67-5]
Dimethyl sulfate [77-78-1]
Ethylene dibromide [106-93-4] . when used as a fumigant
4,4'-Methylene bis(2-chloroaniline) [101-14-4] . MOCA
2-Propiolactone [57-57-8]
o-Toluidine [95-53-4] and
o-Toluidine hydrochloride [636-21-5]
Vinyl chloride monomer [75-01-4]

EXPLANATORY NOTE ON SUBSTANCES IN SCHEDULE 2 WHICH HAVE THERAPEUTIC USES

Schedule 2 to the National Model Regulations for the Control of Scheduled Carcinogenic Substances [NOHSC:1011(1995)] includes some substances that have therapeutic uses. At present, the substances that appear in schedule 2 that have therapeutic uses, or are starting materials for products that have therapeutic uses, include cyclophosphamide (an anti-cancer drug) and acrylonitrile (used to make moulds in dentistry).

Under these national model regulations, employers must notify the relevant public authority of the intention to use a Schedule 2 carcinogenic substance. We accept that the identification of some substances that have therapeutic uses as being carcinogens may cause some concern to those who are receiving these substances and to those who are involved in their use. However, it is important to understand that for these substances that have therapeutic uses, the risks involved with their use have been assessed. Further, the assessments have determined that the benefits achieved from their use greatly outweigh any associated risks and, therefore, they have obtained approval for use.

The above information has been taken directly from the National Model Regulations for the Control of Scheduled Carcinogenic Substances [NOHS:1011(1995)].

Information provided by Mario Froscio, School of Medicine, 22 December 2004